New UTC Suit Aims to Block Launch of Liquidia’s Rival Lung Drug

United Therapeutics Corp. filed a federal lawsuit seeking to block the “imminent” launch of Liquidia Corp.’s Yutrepia, a dry-powder lung-disease treatment that UTC said infringes a patent covering its blockbuster drug Tyvaso DPI.

The Yutrepia prescribing instructions reflect the dosing method claimed in UTC’s patent for Tyvaso, according to a complaint filed May 9 in the US District Court for the Middle District of North Carolina. Both drugs are intended to treat two forms of high blood pressure in the lungs.

“Liquidia has made clear that in just weeks, it plans to launch” Yutrepia “despite the existence of UTC’s patent ...